Etoricoxib for Sciatica

Evidence-Based Rationale

The American College of Physicians/American Pain Society guidelines state that there is little evidence to guide specific recommendations for medications for patients with sciatica, except for gabapentin, which shows small, short-term benefits specifically for radiculopathy 1
Most NSAID trials evaluated nonspecific low back pain or mixed populations, not sciatica specifically, highlighting the need for more targeted research 1

The American Heart Association explicitly states that etoricoxib does not appear to be among the first choices for pain relief with regard to safety, especially in individuals with or at risk for cardiovascular disease 2, 3
Etoricoxib has a high COX-2 selectivity, which increases thrombotic cardiovascular event risk proportional to the patient's baseline cardiovascular risk 3, 4
The MEDAL program showed etoricoxib has similar cardiovascular risk to diclofenac, but diclofenac itself is associated with increased thrombotic events 3, 4

The American College of Physicians recommends acetaminophen, tramadol, or short-term narcotic analgesics for pain control, and gabapentin for radiculopathy-specific pain 1, 2
The American Heart Association's stepped-care approach places non-COX-2-selective NSAIDs before agents with COX-2 activity, such as etoricoxib 2

The American Heart Association specifically cautions against assuming etoricoxib is safer than traditional NSAIDs, due to its high COX-2 selectivity and associated cardiovascular risk 2, 3
Extended courses of etoricoxib should be reserved only for patients showing clear continued benefits without major adverse events, and cardiovascular risk stratification should not be ignored 1, 5